
    
      Radiotherapy alone is commonly used in NK/T-cell lymphoma without adverse risk including
      lymph node involvement, local invasion, B symptoms and high LDH level. Recently, methotrexate
      was prove to be a radiosensitizer in NK/T-cell lymphoma cells. Therefore, the investigators
      aim to verify the superiority and safety of weekly methotrexate in combination with
      radiotherapy in a randomized phase II study.
    
  